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Summary
Introduction: Hepatocellular carcinoma (HCC) is increasing in incidence in the UK and globally. Liver cirrhosis is the com-
mon cause for developing HCC. The common reasons for liver cirrhosis are viral hepatitis C (HCV), viral hepatitis B and alco-
hol. However, HCC caused by non-alcoholic fatty liver disease (NAFLD)-cirrhosis is now increasingly as a result of rising
worldwide obesity.
Aim: To compare the clinical presentation, treatment options and outcomes of HCC due to HCV and NAFLD patients.
Methods: Data were collected from two liver transplant centres in the UK (Birmingham and Newcastle upon Tyne) between
2000 and 2014. We compared 275 patients with HCV-related HCC against 212 patients with NAFLD- related HCC.
Results: Patients in the NAFLD group were found to be significantly older (P < 0.001) and more likely to be Caucasian
(P < 0.001). They had lower rates of cirrhosis (P < 0.001) than those in HCV-HCC group. The NAFLD group presented with sig-
nificantly larger tumours (P ¼ 0.009), whilst HCV patients had a higher alpha fetoprotein (P ¼ 0.018). NAFLD patients were
more commonly treated with TACE (P ¼ 0.005) than the HCV patients, whilst the HCV group were significantly more likely to
be transplanted (P < 0.001). In patients selected for liver transplantation, 5-year survival rates in NAFLD were not signifi-
cantly different from HCV-HCC (44 and 56% respectively, P ¼ 0.102).
Conclusion: In this study, NAFLD patients presented with larger tumours that were less likely to be amenable to curative
therapy, as compared with HCV patients. Despite this disadvantage, patients with NAFLD had similar overall survival com-
pared to patients with HCV.
Received: 5 January 2016; Revised (in revised form): 16 August 2016
VC The Author 2016. Published by Oxford University Press on behalf of the Association of Physicians.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Introduction
Hepatocellular carcinoma (HCC), constituting 70–90% of cases of
primary liver cancer, is the fifth most common cause of cancer
in Europe and a life threatening complication of cirrhosis1
European epidemiological data show that there are 1–13 new
cases of HCC and 1–10 deaths per 100 000 inhabitants per year.1
A study from the USA conducted in 1999 showed increased inci-
dence of HCC in the past two decades.2 Without any treatment,
HCC has a very poor prognosis, with a 5-year survival rate of
around 5%.1 Chronic viral hepatitis, caused by the hepatitis B
virus (HBV) and hepatitis C virus (HCV), is known to be an add-
itional risk factor and there is gathering evidence that HCC
associated with these infections have differences in their mo-
lecular signatures compared to HCC with other causes of cirrho-
sis.3 Recently, there has been a dramatic progress in the
therapeutic options for HBV and HCV infection, leading to ef-
fective viral suppression in HBV and high rates of cure for HCV.4
This will significantly alter the epidemiology of HCC in the fu-
ture with likely decline in viral associated cirrhosis and HCC.
Non-alcoholic fatty liver disease (NALFD) on the other hand is
an emerging public health problem that is an increasing cause
of cirrhosis and HCC.5,6
NAFLD-associated HCC usually occurs at a more advanced
age (4–6 years older) than HCC caused by cirrhosis of other aeti-
ologies.7 In some patients with NAFLD, HCC can occur without
underlying features of liver cirrhosis and a study from USA
showed only 46% of NAFLD- and non-alcoholic steatohepatitis
(NASH)-related HCC patients have underlying cirrhosis.8
Increased body mass is associated with increased risk of all can-
cers, including liver cancer.9 A population study from Sweden
showed threefold higher risk of HCC in obese patients10 and a
Danish study further confirmed twofold increased in liver can-
cer incidence in obese subjects compared with non-obese sub-
jects.11 A recent study from the USA showed that compared
with normal weight individuals, obese individuals had a 2.4-
fold increased risk of liver cancer (OR ¼ 2.38, 95% CI: 1.68–3.36),
and overweight individuals had a 32% increased risk (OR ¼ 1.32,
95% CI: 1.03–1.70).12
Diabetes has been found to increase the risk of developing
chronic liver disease and HCC13 and in a recent systematic re-
view of 13 case-control studies, diabetic subjects were found to
have a twofold increase in the risk of HCC compared with a co-
hort of patients without diabetes.14,15 Although studies have
been conducted to assess the incidence and mortality of HCC in
patients with NAFLD compared with viral hepatitis C related
HCC,16–20 there are limited data on outcomes of patients who
had liver transplantation for NAFLD associated HCC.
With the change in the management of viral hepatitis and
increasing incidence of NAFLD, it is useful to compare the pres-
entation and outcome of HCC in patients with HCV and NAFLD
in a cohort from the UK, in order to help devise future strategies
in surveillance and management of HCC. The aim of this study
was to compare baseline demographic features, tumour charac-
teristics and the clinical outcomes of patients with NAFLD-
associated HCC compared to those with HCV-associated HCC.
Methods
Ethical statement
This was a retrospective study and was registered with NHS
trust audit departments in both units (Newcastle upon Tyne
and Birmingham).
Data were retrospectively collected from all adult patients
(18 years) with HCC secondary to HCV or NAFLD who were
referred to two liver transplant centres in UK (Birmingham and
Newcastle Upon Tyne liver units) between 2000 and 2014.
Patients were excluded if they had both co-existing NAFLD and
HCV.
HCV infection was identified by antibody testing, before
being confirmed with polymerase chain reaction and viral load
tests. The diagnosis of NAFLD was made when there was evi-
dence of liver steatosis on imagining, or the histologic features
of NASH, when available, or cryptogenic cirrhosis in the pres-
ence of metabolic syndrome and without a history of significant
alcohol intake. Metabolic syndrome was defined following the
National Cholesterol Education Program Adult Treatment Plan
III guidelines. Patients with cirrhosis were identified based on
histological features of cirrhosis and/or radiological evidence of
cirrhosis in the context of portal hypertension (ascites, variceal
bleeding, thrombocytopenia or hepatic encephalopathy).
Demographic details (age, gender and ethnicity), alcohol ex-
cess (defined as more than 21 units in men and 14 units in
women), presence of diabetes mellitus (DM) and body mass
index (BMI) were extracted from the patient’s records. Model for
end stage liver disease (MELD) and albumin levels were col-
lected at the time of diagnosis.
Patients who had ultrasound scans suggesting HCC received
further radiological tests, generally magnetic resonance imag-
ing scans, with diagnosis made where a typical vascular pattern
of HCC was detected. Details of tumour characteristics such as
size, numbers, location, vascular invasions and distant organ
metastasis were collected from radiology reports. Alpha-feto
protein (AFP) levels were collected at the time of diagnosis of
HCC.
Statistical analysis
Normally distributed continuous variables were reported as
means and standard deviations, which were compared between
groups using independent samples t-tests. Non-parametric
variables were reported as medians with either the range or
quartiles, with comparisons performed using Mann–Whitney
tests. For the categorical variables, Fisher’s exact tests were
used.
Kaplan-Meier curves were then used to compare survival be-
tween NAFLD and HCV patients, both from diagnosis and from
transplant with comparisons between the disease groups made
using log-rank tests. A Kaplan-Meier approach was also used in
the comparison of transplant rates, with patients censored at
death, in order to account for the timings of transplants and
variable lengths of follow up across patients.
Multivariable cox regression models were then produced, to
test whether the differences in survival from diagnosis between
the two diseases were independent of other potentially con-
founding factors. The disease group was entered into the model
and a forward stepwise approach was used to add independent
predictors of patient survival. Any factors with >10% missing
data that were not found to be significant in this model were
then excluded, and the model re-run, in order to maximize the
available sample size.
All analyses were performed using IBM SPSS Statistics 22
(IBM Corp. Armonk, NY). Missing data were excluded on a per-
analysis basis and P < 0.05 was deemed to be indicative of stat-
istical significance throughout.
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Results
Baseline characteristics
A total of 488 patients with HCC caused by either HCV or NAFLD
presented to the liver transplant centres in Birmingham and
Newcastle upon Tyne between 2000 and 2014. One patient was
excluded due to the presence of co-existing HCV and NAFLD in
this particular patient. Among the final 487 patients
(Birmingham, n ¼ 290 and Newcastle upon Tyne, n ¼ 197), 275
patients had HCC due to HCV and 212 patients had HCC second-
ary to NAFLD. The median duration of follow up was 1 year
(Range: 0, 14 years). 20/275 HCV patients (7%) had co-infection
with viral hepatitis B infection and 2/275 (0.7%) patients had
underlying co-existing human immunodeficiency virus (HIV)
infection.
The mean age of the entire population was 63 years (SD 11.0,
range 30, 91 years) of which 390 were male (80%) and 406 were
Caucasian (83%). Patients with NAFLD were significantly older
than those with HCV at the time of HCC diagnosis (mean age of
69.6 vs. 58.6, respectively, P < 0.001). Patients with NAFLD were
also more likely to be Caucasian (98 vs. 72%, P < 0.001), had
higher BMI (mean 32.3 vs. 26.5, P < 0.001) and were more likely
to have T2DM (72 vs. 24%, P < 0.001) than those who had HCV.
The rate of excess alcohol consumption (>21 units in men and
>14 units in women) were similar in the two groups (14% in
NAFLD vs. 18% in HCV, P ¼ 0.215). At the time of HCC diagnosis,
patients with HCV were more likely to be cirrhotic (99 vs. 87%,
P < 0.001) than those with NAFLD.
The median MELD at diagnosis of HCC was not found to dif-
fer significantly between the two groups (9 in HCV vs. 10 in
NAFLD, P ¼ 0.142). Albumin levels were significantly higher in
NAFLD patients than in HCV (mean 39.3 vs. 37.2 g/l, P ¼ 0.006).
Among 487 patients, 101 patients (21%) (80 HCV and 21 NAFLD)
were transplanted.
Figure 1 and Table 1 summarized the overall patients’ char-
acteristics and their demographics.
Previous HCV treatment
In patients with chronic hepatitis C infection, 74/275 patients
(27%) were previously treated with PEGylated interferon and
ribavirin and among them, 20 patients (27%) responded to the
combination treatment.
HCC characteristics in both patients’ groups
The HCC characteristics for all patients were documented in
Table 2. AFP levels were found to be higher in HCV (median of
32 vs. 12, P ¼ 0.018) than in patients with NAFLD. The majority
of HCCs were found in the right lobe of the liver (59% in NAFLD
vs. 63% in HCV), followed by both lobes and the left lobe, with
distribution of HCCs being similar in the two groups (P ¼ 0.891).
Patients with NAFLD had larger tumours, with 39% of cases
being 5 cm or more, compared with 26% in HCV (P ¼ 0.009). 74%
of NAFLD patients and 76% of HCV patients presented with less
than 3 tumours at the time of first presentation. 18% of patients
from both groups had three to five lesions and <10% of patients
had more than five lesions at time of presentation. 14% of pa-
tients in both groups had evidence of either macro or micro vas-
cular invasion, either from radiological examination or
histologically post-liver transplantation. In the whole cohort,
lymph node metastasis was noted in 2% of cases and distant
organ metastasis was found in 5% of cases at diagnosis.
HCC treatments in both patients’ groups
The summary of HCC treatments in both groups were docu-
mented in Table 3. Patients with NAFLD were more likely to be
treated with trans-arterial chemoembolization (TACE) (41 vs.
28%, P ¼ 0.004). Radiofrequency ablation was used in 15% of pa-
tients, followed by liver resection in 3–4% of cases. Sorafenib
therapy was given in a similar proportion of HCV and NAFLD
cases (5.5 vs. 7.1%, P ¼ 0.569). During the follow up period of 14
years, HCV patients were more likely to undergo liver trans-
plantation (29 vs. 9.9%, P < 0.001). Due to the varying lengths of
follow up, transplantation rates were estimated by a Kaplan-
Meier approach.
Survival data
The survival outcomes for the two groups are reported in Table
4. Overall survival was similar in the two groups, with rates at 3
Figure 1. Flowchart of cohort of patients with HCC.
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years from diagnosis were 21% for HCV and 23% for NAFLD
(P ¼ 0.464, Figure 2).
Since there were large differences in the demographics of
the two groups, a multivariable analysis was then performed
(Table 5). All of the factors in Tables 1–3 were considered for in-
clusion in the model. The analysis found cirrhosis (P ¼ 0.008),
increasing HCC size (P < 0.001) and AFP (P < 0.001) and vascular
invasion (P ¼ 0.001) to be significant predictors of shorter sur-
vival. Treatment with RFA (P ¼ 0.026), liver resection (P ¼ 0.041)
Sorafenib (P < 0.001) and transplant (P ¼ 0.003) were all found to
significantly lengthen survival. After accounting for these fac-
tors, the difference in survival between the two disease groups
remained non-significant (HR: 1.22, 95% CI: 0.97–1.54, P ¼ 0.084).
Univariable analyses of the factors considered are also re-
ported in Supplementary Table S1.
Sub-group analysis
Transplanted cohort
Analysis was also performed on the subgroup of patients that
received liver transplants during the follow up period (n ¼ 101),
all of whom were cirrhotic at the time of listing. Tables 1 and 2
summarize the baseline characteristics and tumour characteris-
tics of the transplanted cohort, as well as comparisons between
HCV and NAFLD. These comparisons returned similar results to
the analysis of the whole patient cohort. The only exceptions
were the analyses of MELD, which was found to be significantly
higher in the transplanted NAFLD cohort (P ¼ 0.024), and the
comparisons of Albumin and tumour size, which became non-
significant on account of the smaller sample size. The post-
transplant survival for patients in both groups were shown in
Figure 3, with 5-year survival rates in NAFLD-HCC were not sig-
nificantly different from HCV-HCC (44 and 56%, respectively, P ¼
0.102). The survival for patients with HCC who did not receive
liver transplantation (n ¼ 386) was poor, with only 4% of HCV and
7% of NAFLD patients surviving 5 years from diagnosis.
Comparison between cirrhotic and non-cirrhotic patients
Patients without cirrhosis were significantly older (mean age of
72 6 11 vs. 63 6 11 years, P < 0.001) compared to cirrhotic pa-
tients. DM was significantly more common in non-cirrhotic pa-
tients (71 vs. 43%, P ¼ 0.003) but the two groups had similar
BMIs (mean 30 6 5 vs. 29 6 5, P ¼ 0.300). MELD was also similar
in the two groups (P ¼ 0.140) but albumin was significantly
higher in non-cirrhotic patients (mean 43.3 6 3.5 vs. 37.6 6 6.0,
P ¼ 0.005). The locations and the numbers of HCCs were similar
in both groups (P ¼ 0.676, 0.645). AFP was similar between the
two groups (P ¼ 0.902). Non-cirrhotic patients were more likely
to undergo liver resections (26 vs. 2%, P < 0.001), with patients
that received liver resection (n ¼ 17) having a significantly
greater 5-year survival rate of 27% compared wtih 11% in non-
liver resected patients (P ¼ 0.001).
None of the patients from non-cirrhotic cohort received liver
transplantation (LT), due to them having large tumour size (69%
being 5 cm), vascular invasion (16%) or the presence of distant
organ metastasis (13%). Despite these differences, survival was
not found to differ significantly between the two cohorts (me-
dian non-cirrhotic 22 months vs. cirrhotic 15 months, P ¼ 0.158,
Figure 4), although the statistical power of this analysis was
low, on account of the small numbers of non-cirrhotic patients.
Comparison between two transplant units
Patient diagnoses differed significantly between the two centres
(P < 0.001), with the Birmingham cohort being predominantly
HCV (73%), whilst the majority of patients from Newcastle had
NAFLD (68%). Patient demographics also differed significantly be-
tween the sites, with patients from Newcastle being significantly
older (P < 0.001), with higher BMI (P ¼ 0.026), and a higher rate of
diabetes (P < 0.001), which is likely reflective of the greater pro-
portion of patients at this site with underlying NAFLD. There
were also significant ethnic differences (P < 0.001), with the
Newcastle cohort being almost entirely Caucasian (96%), com-
pared with 75% in Birmingham (Table 6).
Of the disease-related factors, rates of alcohol excess (20
vs.10%, P ¼ 0.003) and cirrhosis (99 vs. 86%, P < 0.001) were both
significantly higher in Birmingham. No significant differences
in albumin levels, MELD, AFP levels and numbers of HCC were
detected between the cohorts. The sizes of HCC were signifi-
cantly larger in Newcastle patients (P ¼ 0.014). Patients from
Newcastle were more likely to receive TACE therapy (49 vs. 23%,
P < 0.001). Overall median survival of patients was similar in the
two units (16 vs. 13 months, P ¼ 0.927).
Comparison as per time frame
We divided the time frame into two periods: from 2000 to 2008
(n ¼ 220) and from 2009 to 2012 (n ¼ 267), in order to assess
whether patient demographics, disease-related factors or out-
comes varied over the period of the study. All the factors re-
ported in Table 6 were then compared between the patients in
Table 1. Baseline demographics of overall and transplanted cohort
of patients
Total cohort
of patients
Valid
n
HCV
(n ¼ 275)
NAFLD
(n ¼ 212)
P-value
Agea 487 58.6 (10.2) 69.6 (8.7) <0.001*a
BMIa 336 26.5 (5.2) 32.3 (5.6) <0.001*a
Gender (Male) 487 219 (79.6%) 171 (80.7%) 0.820
Ethnicity 487 <0.001*
White 198 (72.0%) 208 (98.1%)
Asian 66 (24.0%) 3 (1.4%)
Black/Mixed 11 (4.0%) 1 (0.5%)
DM (type 2) 487 65 (23.6%) 153 (72.2%) <0.001*
Alcohol Excess 487 50 (18.2%) 29 (13.7%) 0.215
Cirrhotic 487 271 (98.5%) 185 (87.3%) <0.001*
MELDb 287 9 (7 – 11) 10 (8 – 13) 0.142b
Albumina 288 37.2 (6.0) 39.3 (5.6) 0.006*a
Transplanted
cohort of
patients
Valid
n
HCV
(n 5 80)
NAFLD
(n 5 21)
P-value
Agea 101 54.0 (7.2) 58.9 (5.5) 0.005*a
BMIa 98 26.9 (4.5) 32.1 (5.0) <0.001*a
Gender (Male) 101 69 (86%) 18 (86%) 1.000
Ethnicity 101 0.012*
White 58 (73%) 21 (100%)
Asian 20 (25%) 0 (0%)
Black/Mixed 2 (3%) 0 (0%)
DM (type 2) 101 27 (34%) 16 (76%) <0.001*
Alcohol Excess 101 10 (13%) 6 (29%) 0.094
MELDb 101 8 (7–11) 10 (8–15) 0.024*b
Albumina 101 37.9 (5.8) 35.9 (7.3) 0.177a
Data reported as ‘n (%)’, with P-values from Fisher’s exact test, unless stated
otherwise.
aData reported as ‘Mean (SD)’, with P-values from independent samples t-tests.
bData reported as ‘Median (Quartiles)’, with P-values fromMann–Whitney tests.
*Significant at P < 0.05.
4 | QJM: An International Journal of Medicine, 2016, Vol. 0, No. 0
by guest on Novem
ber 8, 2016
D
ow
nloaded from
 
these two time frames. None of the demographic factors were
found to differ significantly between the two periods. Of the dis-
ease-related factors considered, the only significant difference
was in the number of HCCs at presentation, which has reduced
significantly over time (P ¼ 0.016) with 11% of patients in 2000–8
having more than five HCCs, compared with 5% in 2009–12. As
for treatment factors, patients diagnosed in the period 2009–12
were more likely to receive sorafenib (10 vs. 1%, P < 0.001),
since this treatment only became available in 2008. No signifi-
cant difference in survival was detected between the periods
(P ¼ 0.060), with a median of 14 months in 2000–8, compared
with 16 months in 2009–12.
Discussion
HCC remains a common malignancy despite the development
of preventative and therapeutic strategies over the past two
decades, and overall survival remains extremely poor.21,22
Previous studies have shown that survival in HCC depends on
tumour stage, underlying liver function and performance status
of the patient.23. Worldwide, 50% of HCC is caused by HBV, al-
though in western countries, 30% of HCC were related to HCV.21
Other factors noted to increase the risk of cirrhosis and HCC in-
clude alcohol excess, diabetes and obesity.16,24–26 Obesity is
increasing worldwide and a recent meta-analysis of 11 cohort
studies from Europe, the USA and Asia showed that summary
relative risks of HCC were 1.17 (95% CI: 1.02–1.34) for overweight
and 1.89 (95%CI: 1.51-2.36) for obese individuals, compared with
normal-weight individuals.27
In our collaborative study, patients in the NAFLD groups
were significantly older and more likely to be Caucasian in ori-
gin than those with HCV which was also observed by Ascha et
al.16 The findings from a study in the USA demonstrated a sig-
nificantly higher proportion of females in the NAFLD cohort.28
In our UK- based study, we did not detect any differences in
gender between the two cohorts, with a high male preponder-
ance observed in both groups. Our study showed that patients
with NAFLD tend to have larger tumour size, but lower AFP level
compared to those with HCV. NAFLD patients had larger tumour
Table 2. HCC comparisons between the disease groups (overall and
transplanted cohort)
Total cohort
of patients
Valid
n
HCV
(n ¼ 275)
NAFLD
(n ¼ 212)
P-value
Location of HCC 387 0.891
Right 145 (62.5%) 92 (59.4%)
Left 30 (12.9%) 22 (14.2%)
Both 48 (20.7%) 36 (23.2%)
Others 9 (3.9%) 5 (3.2%)
Largest HCC Size (cm) 455 0.009*
<2.0 40 (15.6%) 23 (11.6%)
2.0–4.9 151 (59.0%) 99 (49.7%)
5.0þ 65 (25.4%) 77 (38.7%)
Number of HCC 486 0.520
0–2 208 (75.9%) 156 (73.6%)
3–5 49 (17.9%) 37 (17.5%)
>5 16 (6.2%) 19 (9.0%)
AFPa 458 32 (8 - 199) 12 (4 - 212) 0.018*,a
Vascular Invasionb 487 39 (14.2%) 29 (13.7%) 0.896
Lymph nodes 487 7 (2.5%) 4 (1.9%) 0.763
Distant Organ Mets 487 11 (4.0%) 13 (6.1%) 0.298
Transplanted cohort
of patients
Valid
n
HCV
(n ¼ 80)
NAFLD
(n ¼ 21)
P-value
Location of HCC 86 0.757
Right 39 (57%) 9 (50%)
Left 5 (7%) 1 (6%)
Both 17 (25%) 7 (39%)
Others 7 (10%) 1 (6%)
Largest HCC Size (cm) 101 0.150
<2.0 18 (23%) 8 (38%)
2.0–4.9 61 (76%) 12 (57%)
5.0þ 1 (1%) 1 (5%)
Number of HCC 101 0.471
0–2 61 (76%) 18 (86%)
3–5 16 (20%) 2 (10%)
>5 3 (4%) 1 (5%)
AFPa 99 11 (5–39) 5 (3–8) 0.006*,a
Data reported as ‘n (%)’, with P-values from Fisher’s exact test, unless stated
otherwise.
aData reported as ‘Median (Quartiles)’, with P-values from Mann–Whitney tests.
bindicates either radiological or histological evidence.
*Significant at P < 0.05.
Table 3. Treatment comparisons between the disease groups
Valid n HCV (n ¼ 275) NAFLD (n ¼ 212) P-value
Radio frequency ablation (RFA) 487 42 (15.4%) 29 (13.7%) 0.698
Trans arterial chemo-embolization (TACE) 487 78 (28.4%) 87 (41.0%) 0.004*
Liver resection 487 8 (2.9%) 9 (4.2%) 0.463
Percutaneous ethanol Injection (PEI) 487 9 (3.3%) 4 (1.9%) 0.407
Sorafenib therapy 487 15 (5.5%) 15 (7.1%) 0.569
Liver transplantation rates over 14 years follow up 487 80 (29.1%) 21 (9.9%) <0.001
Liver transplantation by 5 yearsa 487 56.3% 16.8% <0.001*a
Data reported as ‘n (%)’, with P-values from Fisher’s exact test.
aKaplan-Meier estimated rate, censored at death, with P-values from log-rank test.
*Significant at P < 0.05.
Table 4. Survival rates of patients with HCC
n 1 year 3 years 5 years P-values
Overall survival from diagnosis 0.464
HCV 275 57.6% (3.2%) 21.1% (2.8%) 11.9% (2.3%)
NAFLD 212 55.5% (3.5%) 22.9% (3.0%) 10.5% (2.3%)
Survival from diagnosis for non-OLT patients 0.157
HCV 195 46.2% (3.7%) 10.1% (2.3%) 3.7% (1.5%)
NAFLD 191 51.6% (3.7%) 18.2% (2.9%) 6.8% (2.0%)
OLT, orthoptic liver transplantation; HCV, hepatitis C viral infection; NAFLD,
non-alcoholic fatty liver disease.
Data reported as ‘Kaplan-Meier estimate (SE)’ with P-values from log-rank tests.
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size at diagnosis, probably due to lower rate of detection with
ultrasound likely to be limited by presence of central abdominal
obesity as well as under-estimation of the degree of fibrosis
which can then reduce the rate of surveillance in this cohort of
patients.
With the increasing use of fibroscan with larger probes,
more patients with NAFLD are being assessed for the presence
of significant fibrosis and the debate is still ongoing for perform-
ing HCC surveillance in patients with F3 fibrosis. Interestingly,
despite having larger tumours, the rates of vascular invasion,
lymph node or distant organ metastasis were similar in the two
groups. In our cohort, 13% of NAFLD patients were not cirrhotic
at the time of HCC diagnosis. In the non-cirrhotic cohort, pa-
tients were significantly older with higher diabetes rate and sig-
nificantly larger tumour size. In this cohort of non-cirrhotic
patients, 26% received liver resection but none received LT due
to either tumour size outside transplant criteria, vascular inva-
sion or distant organ metastasis
In our study, NAFLD patients were more commonly treated
with TACE than the HCV group, whilst the HCV group were sig-
nificantly more likely to be transplanted. The liver resection
rate was low in both of our cohorts because of the underlying
degree of liver fibrosis as well as associated co-morbidities in
NAFLD cohort. In regard to time line, we found that sorafenib
was used more commonly between 2009 and 2012, since the
phase 3 clinical trial of sorafenib was published in 2008.28
Our patients had comparable rates of transplantation to the
previous study performed by Ascha et al.16 in which 29% under-
went liver transplantation and in our study, crude rate of liver
transplantation over 14 years of follow up as 21% (101/487 ¼
21%). In our data, more patients (29.1%) of HCV-HCC were trans-
planted compared with 9.9% of NAFLD-HCC patients. These dif-
ference were likely to be due to unfavourable patient
characteristics in NAFLD cohort (older, more likely to be diabetic
and higher BMI) as well as larger tumour sizes. Although 50%
survival at 5 years makes liver transplantation, comparatively,
one of the best treatments for hepatocellular cancer, it raises
the question as to whether this is an appropriate use of limited
organ resources. Utilizing cut-off AFP value as an added selec-
tion criterion during LT assessment will hopefully reduce future
deaths from post-transplant recurrence.28,29
Furthermore, a proportion of patients with HCV develop se-
vere HCV recurrence in the liver graft post-LT. However, the re-
cent development in newer antiviral therapy with high
Table 5.Multivariable analysis of survival in all patients
HR (95% CI) P-value
Disease (NAFLD) 1.22 (0.97–1.54) 0.084
Cirrhotic 1.91 (1.18–3.08) 0.008*
Largest HCC Size (cm) <0.001*
<2.0
2.0-4.9 1.84 (1.28–2.63) <0.001*
5.0þ 2.68 (1.77–4.04) <0.001*
AFP <0.001*
<5
5–24 1.34 (0.98–1.83) 0.068
25–249 1.80 (1.32–2.47) <0.001*
250þ 2.14 (1.53–3.01) <0.001*
Vascular invasion 1.79 (1.26–2.53) 0.001*
Radiofrequency ablation 0.69 (0.50–0.96) 0.026*
Liver resection 0.51 (0.27–0.97) 0.041*
Sorafenib therapy 0.31 (0.20–0.48) <0.001*
Transplanteda 0.55 (0.37–0.82) 0.003*
Results from a multivariable cox regression model, using a forward stepwise
entry procedure. The disease group was forced into the model, and factors in
Tables 1–3 were considered for inclusion as additional confounders. The initial
model did not identify any of the factors with >10% missing data as significant
predictors of survival, hence these were excluded to maximize the available
sample size, and the model re-run. The final model was based on the n ¼ 355
cases with data available for all of the factors considered.
HR, hazard ratio.
aTreated as a time-dependent covariate, in order to account for the effect of sur-
vivor bias.
*Significant at P < 0.05.
Figure 2. Kaplan-Meier curves for overall survival of patients with HCC. HCV, Hepatitis C viral infection; NAFLD, non-alcoholic fatty liver disease.
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sustained virologic response rates should also impact on out-
come for patients with HCV transplanted for HCC.30–32 This
should hopefully prevent graft loss from recurrent HCV but we
should be cautious regarding HCC recurrence rates in individual
treated with newer agents due to a recent study in the pre-
transplant population.33 In this particular study, 103 patients
who received direct acting anti-viral (DAA), 16 (27.6%) developed
radiological recurrence of tumour.33 NAFLD post-transplant sur-
vival rates did not significantly differ from HCV patients but
were below 50% at 5 years. The total numbers were small to
draw definite conclusions but utilizing cut off AFP values and
improved risk stratification of cardiovascular co-morbidity will
hopefully improve outcomes in the future.
In our cohort, a much higher proportion of HCV patients
were transplanted compared with NAFLD patients and the rea-
sons behind was likely multifactorial including: their younger
age at presentation, increased likelihood of being cirrhotic at
presentation, the reduced rate of underlying co-morbidities es-
pecially cardiovascular risk factors and lower BMI with reduced
surgical risk. Due to this lower risk, the HCV patients are also
more likely to be allocated livers from donors after circulatory
death, widening the pool of available organs for these patients.
Furthermore, in terms of tumour biology NALFD patients had
larger tumours at presentation although other factors such as
number of tumours, extra hepatic spread were similar and AFP
values were lower than HCV patients.
When we compared the two units (Birmingham and
Newcastle), we found that patients from Newcastle had higher
risk baseline demographics (patients were older, higher BMI and
more likely to be diabetic) than Birmingham, reflected in fact
that the majority of patients from Newcastle having underlying
NAFLD rather than HCV. As per tumour characteristics, more
patients from Newcastle received TACE treatment, which was
attributed to the higher proportion of NAFLD associated HCC
patients, and the less favourable patient and tumour
characteristics.
There are limitations with our study, one being the retro-
spective nature of the data collection and analysis. Data were
incomplete for some of the variables, most noticeably for MELD
and albumin data. It is also important to highlight that these
Figure 3. Kaplan-Meier curves for post-transplant survival of patients receiving
transplants for HCC. HCV, Hepatitis C viral infection; NAFLD, non-alcoholic fatty
liver disease.
Figure 4. Kaplan-Meier survival curve for patients with cirrhosis and without
cirrhosis.
Table 6. Comparison between all the patients treated at the two
transplant centres
Valid
n
Birmingham
(n ¼ 290)
Newcastle
(n ¼ 197)
P-value
Disease 487 <0.001*
HCV 212 (73.1%) 63 (32.0%)
NAFLD 78 (26.9%) 134 (68.0%)
Agea 487 60.1 (10.5) 68.2 (10.0) <0.001*,a
BMIa 336 28.6 (6.0) 30.1 (6.2) 0.026*,a
Gender (Male) 487 237 (81.7%) 153 (77.7%) 0.299
Ethnicity 487 <0.001*
White 217 (74.8%) 189 (95.9%)
Asian 64 (22.1%) 5 (2.5%)
Mixed/Black 9 (3.1%) 3 (1.5%)
DM (type 2) 487 91 (31.4%) 127 (64.5%) <0.001*
MELDb 287 9 (8 - 12) 10 (7–15) 0.328b
Albumina 288 38.0 (6.0) 36.5 (5.6) 0.188a
Alcohol excess 487 59 (20.3%) 20 (10.2%) 0.003*
Cirrhotic 487 286 (98.6%) 170 (86.3%) <0.001*
Location of HCC 387 0.493
Right 173 (60.3%) 64 (64.0%)
Left 36 (12.5%) 16 (16.0%)
Both 66 (23.0%) 18 (18.0%)
Other 12 (4.2%) 2 (2.0%)
Largest HCC
size (cm)
455 0.014*
<2.0 43 (16.0%) 20 (10.7%)
2.0–4.9 155 (57.8%) 95 (50.8%)
5.0þ 70 (26.1%) 72 (38.5%)
Number of HCC 486 0.073
0–2 226 (78.2%) 138 (70.1%)
3–5 47 (16.3%) 39 (19.8%)
>5 16 (5.5%) 20 (10.2%)
AFPb 458 27 (6 - 237) 19 (4–179) 0.179b
RFA 487 38 (13.1%) 33 (16.8%) 0.296
TACE 487 68 (23.4%) 97 (49.2%) <0.001*
Liver resection 487 10 (3.4%) 7 (3.6%) 1.000
PEI/alcohol injection 487 13 (4.5%) 0 (0.0%) 0.001*
Sorafenib 487 20 (6.9%) 10 (5.1%) 0.449
Liver transplantation 487 75 (25.9%) 26 (13.2%) <0.001
Median survival
(months)c
487 16.1 (SE¼ 1.5) 12.8 (SE¼ 1.5) 0.927c
Data reported as ‘n (%)’, with P-values from Fisher’s exact test, unless stated
otherwise.
aData reported as ‘Mean (SD)’, with P-values from independent samples t-tests.
bData reported as ‘Median (Quartiles)’, with P-values from Mann–Whitney tests.
cData reported as ‘Kaplan Meier Estimated Rate (SE)’ or ‘Median Survival (SE)’,
with P-values from log-rank tests.
*Significant at P < 0.05.
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are the data from patients presented to tertiary centre liver
transplant units in which patients were managed in a multidis-
ciplinary team, and so further studies are required for presenta-
tion of HCC in secondary and primary care. In terms of therapy,
we can demonstrate that the majority of patients in both co-
horts present with advanced/incurable disease. It is therefore
clear that further work is required to improve future risk stratifi-
cation and early stage diagnosis, irrespective of how HCC epi-
demiology changes in the future.
Conclusion
Despite being older with more metabolic risk factors as well as
presenting with larger tumours, a significant proportion of pa-
tients with NAFLD are able to tolerate loco-regional therapy
such as TACE or RFA and have similar overall survival com-
pared to those with HCV with lower tumour burden.
The new era of anti-viral therapies has transformed our care
of patients with chronic hepatitis C. These newer agents with
excellent sustained virological response may reduce the inci-
dence of HCC in HCV cohort in the near future. However, the
overall incidence of HCC is likely to increase as a result of wor-
sening incidence of obesity worldwide with increased incidence
of NAFLD. Hence, it is important to understand the nature of
HCC in patients with NAFLD in order to plan future surveillance
and therapeutic approaches.
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